Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies

Leuk Lymphoma. 2015 Apr;56(4):1151-3. doi: 10.3109/10428194.2014.951843. Epub 2014 Oct 7.

Authors

Andres Forero-Torres¹, Nancy L Bartlett, Robert B Berryman, Robert Chen, Jeffrey V Matous, Michelle A Fanale, Owen A O'Connor, Randal Olshefski, Scott E Smith, Dirk Huebner, Pamela L Levine, Laurie E Grove, Ajay K Gopal

Affiliation

¹ University of Alabama at Birmingham , Birmingham, AL , USA.

PMID: 25110824
DOI: 10.3109/10428194.2014.951843

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Brentuximab Vedotin
Drug Administration Schedule
Drug Resistance, Neoplasm
Fatigue / chemically induced
Female
Headache / chemically induced
Hematologic Neoplasms / drug therapy*
Hematologic Neoplasms / metabolism
Humans
Immunoconjugates / adverse effects
Immunoconjugates / therapeutic use*
Infections / chemically induced
Ki-1 Antigen / metabolism*
Male
Middle Aged
Nervous System Diseases / chemically induced
Recurrence
Spasm / chemically induced
Young Adult

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin